Profound Medical Corp.

PRN

CA74319B5027

Advanced Medical Equipment & Technology

Delayed Toronto S.E. Other stock markets 11:55:40 2024-06-03 EDT			5-day change	1st Jan Change
10.28 ^CAD	+2.70%		+5.33%	-7.39%

05-15	Transcript : Profound Medical Corp. - Shareholder/Analyst Call
05-14	Sector Update: Health Care Stocks Steady Premarket Tuesday	MT

Profound Medical Corp. Announces Resignation of Ian Heynen as Senior Vice-President of Sale and Marketing, Effective January 7, 2019

December 14, 2018 at 08:04 am

Profound Medical Corp. announced that Ian Heynen will be resigning from his position as Senior Vice-President of Sale and Marketing to pursue other opportunities, effective January 7, 2019.

Latest news about Profound Medical Corp.

Transcript : Profound Medical Corp. - Shareholder/Analyst Call	05-15
Sector Update: Health Care Stocks Steady Premarket Tuesday	05-14	MT
Profound Medical Receives FDA Approval for AI-Powered Prostate Disease Device --Shares Advance Pre-Bell	05-14	MT
Profound Medical Receives U.S. FDA Clearance for "Contouring Assistant" AI Module	05-14	MT
Profound Medical Brief: Says Received U.S. FDA 510(k) Clearance for 'Contouring Assistant' AI Module that Enables Creation of an Automated TULSA Treatment Plan	05-14	MT
Profound Medical Receives U.S. FDA 510(K) Clearance for Contour Assistant AI Module That Enables Creation of an Automated Tulsa Treatment Plan	05-14	CI
Profound Reports a Narrower First-Quarter Loss; Provides 2024 Revenue Guidance	05-09	MT
Transcript : Profound Medical Corp., Q1 2024 Earnings Call, May 09, 2024	05-09
Profound Medical Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Profound Medical Brief: Expects total revenue for FY24 to be in the range of US$11.0-$12.0 million, which represents 53% to 67% growth compared to its prior year revenue	05-09	MT
Profound Medical Brief: Recorded Q1 revenue of approximately $1.91 million, with $1.48 million from recurring revenue; Issues Full-Year 2024 Revenue Guidance	05-09	MT
Profound Medical Corp. Provides Earnings Guidance for Full-Year 2024	05-09	CI
Profound Medical Says Clinical Evidence Points to Potential of Its TULSA Procedure as a Treatment for Prostate Cancer	05-06	MT
Profound Medical Brief: Adds Clinical evidence Continues to highlight TULSA's "Ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH"	05-06	MT
Profound Medical Brief: Says "Growing Body of Clinical Evidence" Points to Potential of Its TULSA Procedure "Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum"	05-06	MT
Transcript : Profound Medical Corp. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 11:15 AM	03-13
Alliance Global Partners Trims Price Target on Profound Medical to $10.80 From $12.75, Maintains Buy Rating	03-11	MT
Stifel Adjusts Price Target on Profound Medical to $9 From $11, Keeps Hold Rating	03-08	MT
Profound Medical Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	03-07	CI
Transcript : Profound Medical Corp., Q4 2023 Earnings Call, Mar 07, 2024	03-07
Profound Medical Reports Q4 Net Loss of US$0.42 Per Share, Announces COO Appointment	03-07	MT
Profound Medical Brief: Announcing promotion of Mathieu Burtnyk, from SVP Product Leader to Chief Operating Officer	03-07	MT
Profound Medical Brief: Q4 2023 net loss was approximately US$8.9 million, or $0.42 per common share	03-07	MT
North American Morning Briefing : Powell Still in the Spotlight; ECB Rate Decision Looms	03-07	DJ
Profound Medical Collaborates With Siemens Healthineers to Expand Physician and Patient Access to the TULSA Procedure	02-27	MT

Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum. TULSA-PRO has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer and the transition zone in large volume benign prostatic hyperplasia. It is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Profound Medical Corp.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

10.01 CAD

Average target price

12.5 CAD

Spread / Average Target

+24.88%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
PROFOUND MEDICAL CORP.	-7.39%	179M
THERMO FISHER SCIENTIFIC	+6.33%	217B
DANAHER CORPORATION	+11.71%	190B
INTUITIVE SURGICAL, INC.	+18.39%	143B
BOSTON SCIENTIFIC CORPORATION	+29.82%	111B
SIEMENS HEALTHINEERS AG	+0.65%	64.59B
EDWARDS LIFESCIENCES CORPORATION	+14.37%	52.36B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+2.06%	48.45B
AGILENT TECHNOLOGIES, INC.	-4.92%	38.03B
GE HEALTHCARE TECHNOLOGIES INC.	-0.83%	35.6B

Other Advanced Medical Equipment & Technology